DNase

Phase 3Protein / enzyme

TThe Hospital for Sick Children

DNase is one of 5 small molecule programs targeting Empyema. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EmpyemaActive, not recruiting

EmpyemaPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Empyema

#DrugCompanyPhaseTrials

Betadine

BBecton, Dickinson and Company

Activase

1 3

Urokinase

Mmedac GmbH

Phase 3

1 4

Tpa

UUniversity of Florida

Phase 3

1 5

DNase

TThe Hospital for Sick Children

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thoracoscopy1 trial

Fibrinolytic Therapy Versus Medical Thoracoscopy

Completed·UUniversity of Florida·Phase 4·NCT03213834·5 enrolled

Empyema1 trial

Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)

Completed·TThe Hospital for Sick Children·Phase 3·NCT01717742·97 enrolled

Treatment1 trial

DNase Treatment for Dry Eyes

Terminated·UUniversity of Illinois at Chicago·Phase 1/2·NCT02193490·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for DNase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DNase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DNase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Hospital for Sick Children company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: TThe Hospital for Sick Children

DNase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thoracoscopy1 trial

Empyema1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News